Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events

Platelets

Volumn 16, Issue 8, 2005, Pages 462-468

  Dunkley, Scott ^a   Evans, Sue ^a   Gaudry, Leonie ^a   Jepson, Nigel ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Drug dependent antibodies; Platelet activation; Thrombocytopenia; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; LIPOCORTIN 5; PADGEM PROTEIN; THROMBOCYTE ANTIBODY; TIROFIBAN;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TYROSINE;

EID: 30944449768     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500140141     Document Type: Article

References (24)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. New Engl J Med 1994;330:956-961.
2. Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RH. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orofiban: Evidence of an immune etiology. Thrombosis and Haemostasis 2002;88:892-897.
3. The TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for ischemic events with percutaneous coronary revascularisation. New Engl J Med 2001;344:1888-1894.
4. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/ IIIa. Blood 2002;100:2071-2076.
5. Seiffert D, Stern AM, Ebling W, Rossi RJ, Barrett YC, Wynn R, Hollis GF, He Bokang, Kieras CJ, Pedicord DL, Cromley DA, Tsushung AH, Stein RB, Daly RN, Sferruzza A, Pieniaszek HJ, Billheimer JT. Prospective testing for drug dependent antibodies reduces the incidence of thrombocytopenia observed with small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 2003;101:58-63.
6. Curtis BR, Dvigi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. Journal of Thrombosis and Haemostasis 2004;2:985-992.
7. Nurden P, Clofent-Sanchez G, Jais C, Bermejo E, Leroux L, Coste P, Nurden AT. Delayed immunologic thrombocytopenia induced by abciximab. Journal of Thrombosis and Haemostasis 2004;92: 820-828.
8. Abrams CS, Cines DB. Platelet glycoprotein GPIIb/IIIa inhibitors and thrombocytopenia: Possible link between platelet activation, autoimmunity and thrombosis. Thrombosis and Haemostasis 2002;88:888-889.
9. Dunkley S, Lindeman R, Evans S, Casten R, Jepson N. Evidence of platelet activation due to tirofiban dependent platelet antibodies: Double trouble. Journal of Thrombosis and Haemostasis 2003;1:2248-2250.
10. Pedicord DL, Dicker I, O'Neil K, Breth L, Wynn R, Hollis GF, Billheimer JT, Stern AM and Seiffert D. CD32-dependent platelet activation by a drug dependent antibody to glycoprotein IIb/IIIa antagonists. Thrombosis and Haemostesis 2003;89:513-521.
11. Morel O, Jesel L, Chauvin M, Freyssinet JM, Toti F. Eptifibatide induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. Journal of Thrombosis Haemostesis 2003;1:2685-2687.
12. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203-2206.
13. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thrombosis and Haemostesis 1993;69:344-350.
14. Tzima E, Walker JH. Platelet annexin V: The ins and outs. Platelets 2000:11;245-251.
15. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88:194-201.
16. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin induced thrombocytopenia. British Journal of Haematology 1997;98:648-656.
17. Risch L. Bertschmann W. Heijnen IA. Huber AR. A differentiated approach to assess the diagnostic usefulness of a rapid particle gel immunoassay for the detection of antibodies against heparin-platelet factor 4 in cardiac surgery patients. Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis 2003;14:99-106.
18. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998;338:1488-1497.
19. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl J Med 1998;338:1498-1505.
20. Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Current Hematology Reports 2004;3:143-147.
21. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischaemia. Thrombosis and Heamostasis 1999;81:373-377.
22. Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, Koksch M. P-selectin expression, and platelet-derived microparticle formation are increased in peripheral artery disease. Blood Coag Fibrinol 2000;11:723-728.
23. Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: Basic and clinical aspects. Arterioscler Thromb Vasc Biol 1999;19:2835-2840.
24. Contreras M. The appropriate use of platelets: An update from the Edinburgh consensus conference. British Journal of Haematology 1998;101(Suppl 1):10-12.